The Norwegian Association for Cystic Fibrosis (NFCF) is an interest organization that focuses on people with cystic fibrosis (CF) and primary ciliary dyskinesia (PCD), as well as their relatives. The association aims to safeguard the interests of these groups and works to improve the quality of life for those affected by rare diseases. NFCF has approximately 1,100 members and provides support and information to both patients and families.
The association is linked to the public health system and collaborates with the Norwegian Center for Cystic Fibrosis (NSCF), which is established at Oslo University Hospital. NFCF is also part of the National Competence Service for Rare Diagnoses (NKSD). In 2026, the association will celebrate its 50th anniversary, and a family and peer weekend is planned in 2025. In addition, a new treatment, Alyftrek, for cystic fibrosis has recently been approved in the EU, which may have implications for patients in Norway.